Erlotero 150 mg Tablet

Product Description

Erlotero 150 mg Tablet is a targeted anticancer treatment specifically designed for patients battling non-small cell lung cancer (NSCLC) and pancreatic cancer. This medication works by inhibiting the action of epidermal growth factor receptors (EGFR), which are often overactive in these types of cancer, thereby slowing down tumor growth and progression. It is essential for patients to understand that while Erlotero can be effective, it may also lead to side effects such as skin rashes, diarrhea, or liver complications, necessitating regular monitoring by healthcare professionals. Prior to initiating treatment, patients should discuss their medical history, particularly any pre-existing liver conditions or potential drug interactions, with their doctor. Additionally, Erlotero is not recommended for use during pregnancy due to potential risks to the fetus. With careful management and adherence to prescribed regimens, Erlotero 150 mg Tablet can play a crucial role in the comprehensive treatment plan for eligible cancer patients. Always consult with your healthcare provider to determine if this medication aligns with your specific treatment goals and needs.